This report was our free report of the day on a previous date — it has since expired.

Today's free report is available: CNXC 10-Q — Concentrix swings to $988M loss on $1.05B goodwill impairment; revenue slips 1.2%

Sign up free to read 3 full reports/month

Get notified when INBP files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Covenant Violation (new) — The company did not meet its fixed charge coverage ratio of 1.10 to 1.0 and has requested a waiver from PNC, indicating financial stress.
  • Auditor Change (unchanged) — Auditor changed from Marcum to CBIZ; the change appears routine with no disagreements or reportable events disclosed.
OTC: INBP INTEGRATED BIOPHARMA INC 10-K

Integrated BioPharma swings to -$2.8M net loss as sales fall 19.3% and margins compress

Filed September 25, 2026 · Period ending June 30, 2026 · Compared to 10-K Sep 23, 2025 · ~1 min read

Key Changes

  • high

    Net sales fell 19.3% to $43.9M, swinging to a $2.8M net loss ($0.09 diluted EPS) from a $0.8M profit a year earlier.

  • high

    Operating income swung from a $2.0M profit to a $2.7M loss, a $4.7M deterioration, as gross margin collapsed from 10.2% to 1.8%.

  • high

    Customer concentration rose to 90% of consolidated net sales from two customers (Life Extension and Herbalife), up from 84% last year.

    Risk Factors verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Partner

Trade INBP commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 25, 2026 · How we verify